不同药物辅助治疗卵巢子宫内膜异位囊肿的效果及预后分析

Analysis of effect and prognosis of different drugs in adjuvant treatment of ovarian endometriosis cyst

目的分析不同药物辅助治疗卵巢子宫内膜异位囊肿(OEMC)的效果及预后。方法选取2019年6月至2022年6月我院收治的100例OEMC患者为研究对象,以入院先后顺序将其分为对照组与研究组,每组50例。两组均行腹腔镜OEMC切除术治疗,在此基础上,对照组采用亮丙瑞林治疗,研究组采用地诺孕素治疗。比较两组的治疗效果。结果两组的治疗总有效率无明显差异(P>0.05)。治疗后,两组的子宫内膜厚度、抗苗勒管激素、卵巢基质血流阻力指数及卵巢基质血流搏动指数低于治疗前,窦卵泡个数多于治疗前(P<0.05);治疗后,两组的子宫内膜厚度、抗苗勒管激素、窦卵泡个数、卵巢基质血流阻力指数及卵巢基质血流搏动指数无明显差异(P>0.05)。治疗后,两组的微血管数量、CC趋化因子受体9(CCR9)及CC趋化因子配体25(CCL25)低于治疗前,5-脂氧酶(5-LOX)及脂氧素A4(LXA4)高于治疗前(P<0.05);治疗后,两组患者的微血管数量、5-LOX、LXA4、CCR9及CCL25无明显差异(P>0.05)。随访6个月,两组月经停闭及停药后月经恢复的例数无明显差异(P>0.05)。结论亮丙瑞林与地诺孕素辅助治疗OEMC均能获得良好的效果及预后,临床中具体药物选择可根据患者的需要进行调整。

Objective To analyze the effect and prognosis of different drugs in adjuvant treatment of ovarian endometriosis cyst(OEMC).Methods A total of 100 patients with OEMC admitted in our hospital from June 2019 to June 2022 were selected as the research objects.The patients were divided into control group and study group according to the order of admission,with 50 cases in each group.Both groups were treated with laparoscopic OEMC resection.On this basis,the control group was treated with leuprorelin,and the study group was treated with dienogest.The therapeutic effects of the two groups were compared.Results There was no significant difference in the total effective rate between the two groups(P>0.05).After treatment,the endometrial thickness,anti-Mullerian hormone,ovarian stromal blood flow resistance index and ovarian stromal blood flow pulsation index of the two groups were lower than those before treatment,and the number of antral follicles was higher than that before treatment(P<0.05);after treatment,there were no significant differences in endometrial thickness,anti-Mullerian hormone,number of antral follicles,ovarian stromal blood flow resistance index and ovarian stromal blood flow pulsation index between the two groups(P>0.05).After treatment,the microvessel quantity,CC chemokine receptor 9(CCR9)and CC chemokineligand 25(CCL25)of the two groups were lower than those before treatment,5-lipoxygenase(5-LOX)and lipoxin A4(LXA4)were higher than those before treatment(P<0.05);after treatment,there were no significant differences in microvessel quantity,5-LOX,LXA4,CCR9 and CCL25 between the two groups(P>0.05).After 6 months of follow-up,there were no significant differences in the number of cases of menstrual arrest and menstrual recovery after drug withdrawal between the two groups(P>0.05).Conclusion Both leuprorelin and dienogest can achieve good efficacy and prognosis in the adjuvant treatment of OEMC,the specific drug selection in clinical practice can be adjusted according to the needs of patients.